{"title": "Facing Roche threat, Regeneron eyes June approval for high-dose version of Eylea", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/pharma/regeneron-eyes-potential-june-approval-high-dose-version-eylea", "hostname": "fiercepharma.com", "description": "With Vabysmo, Roche was first to the market with a long-acting treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). | With Vabysmo, Roche was first to the market with a long-acting treatment for macular degeneration. But Regeneron is countering quickly in development of its souped-up version of powerhouse Eylea. On Thursday, Regeneron said that the FDA has accepted for priority review its biologics license application for 8 mg Eylea. The regulator assigned a decision date of June 27.", "sitename": "FiercePharma", "date": "2023-02-23", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}